[CLSTR]
< Back to situation

[REVISION HISTORY]

Serbia‑Russia mRNA cancer vaccine partnership

Updated 3 times since CLSTR started tracking revisions of this situation.

What changed

2026-07-31 06:07 UTC → 2026-07-31 06:14 UTC · added removed

In early July 2026 a Serbian delegation led by Minister without Portfolio Nenad Popović met Russian health officials in Moscow to lay the groundwork for Serbian access to Russia’s personalized mRNA cancer vaccine, NEOONKOVAK. The talks aimed at creating an institutional framework for treating Serbian patients in Russia and eventually transferring production steps to Serbia. By late July the collaboration moved to clinical use: a Serbian patient was scheduled to receive the vaccine in August, joining a very limited Russian rollout that had treated only two patients so far. On 28 July 2026 for treatment and Russia formally approved NEOONKOVAK the vaccine for adult patients with inoperable or metastatic melanoma, melanoma on 28 July, marking the world’s first approval of an mRNA anti‑tumor vaccine. Director Academician Alexander Gintsburg highlighted encouraging early results but stressed the need for larger, longer‑term trials. The World Health Organization noted that no mRNA cancer vaccine is yet approved for routine use, underscoring the experimental nature of the therapy while confirming its status as a landmark step in personalized oncology. A report from the Gamaleya Institute on 31 On 30 July 2026 described a strong immune response in Russian scientists reported that the first treated patient – dose administered to a 60‑year‑old man with stage‑3 stage III melanoma – indicating the vaccine effectively targeted the tumor’s mutation profile. Gintsburg said the response exceeded expectations and metastases produced a strong immune response that exceeded expectations. The Gamaleya Research Institute plans to prepare vaccines for ten more additional patients could be prepared within the next one and a half to three months. The Russian Health Ministry plans months, aiming to vaccinate treat up to 20 melanoma patients by year‑end, with production scaling in the coming months, further solidifying year‑end. Researchers are also extending the rollout that Serbia hopes personalized‑vaccine platform to tap into. pancreatic, kidney and small‑cell lung cancers. These developments keep the partnership on track, with Serbia positioned to benefit from Russia’s expanding clinical program programme and forthcoming manufacturing capacity.

Versions

  1. 2026-07-31 06:14 UTC Serbia‑Russia mRNA cancer vaccine partnership
  2. 2026-07-31 06:07 UTC Serbia‑Russia mRNA cancer vaccine partnership
  3. 2026-07-28 11:03 UTC Serbia‑Russia mRNA cancer vaccine partnership
  4. 2026-07-26 09:40 UTC Serbia‑Russia mRNA cancer vaccine partnership

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.